Early data indicates an AI-generated drug could slow aging

5 min readNew DelhiSep 8, 2026 08:38 AM IST

A new report suggests that attracting and retaining top researchers may be a more decisive factor in the global AI race than chips, computing power, or infrastructure. (Image for representation/Magnific)

Last year, a clinical trial conducted by Insilico Medicine, a company that aims to accelerate drug discovery using artificial intelligence, indicated that one of its drug candidates could help treat patients suffering from a chronic lung disease.

Now, the company says data from the same clinical trial shows a more intriguing possibility: that the drug could also slow the aging process.

The molecular structure of the drug, called rentosertib, was generated with the assistance of AI. Results of the new study, published Monday in the journal Nature Biotechnology, show that the drug reduced the biological markers of age as measured by six “aging clocks,” a different kind of AI technology designed to predict a person’s morbidity and mortality.

This elaborate clinical trial is a milestone in the widespread effort to improve healthcare using the same AI techniques that underpin popular chatbots such as ChatGPT and image generators such as Midjourney. Insilico is just one of many startups, tech giants and academic labs working to accelerate drug discovery and hone other medical tasks with help from these methods.

The recent rise of aging clocks is helping to push these efforts beyond short-term treatments and into the realm of longevity research. These systems estimate how quickly a person’s body is aging — or even how quickly individual organs are aging relative to the rest of the body. But scientists continue to debate how much useful information these so-called clocks are able to provide.

“This drug looks encouraging,” said Eric Topol, a cardiologist and the author of the book “Super Agers.” “But we do not yet have a definitive trial to make the final judgment.”

Story continues below this ad

Story continues below this ad